Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma

World Journal of Surgical Oncology

Research

Zhijun Wang¹  Shichun Lu²  Tao Wan²  Wenwen Zhang²  Bingyang Hu²  Yafei Wang²  Junfeng Li³  Tianyu Jiao³  Ze Zhang³ 

[1] Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China;Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China;Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China;Key Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, China;Medical School of Chinese People’s Liberation Army (PLA), Beijing, China;Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China;Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China;Key Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, China;

关键词: Hepatocellular carcinoma;    Recurrence;    Tyrosine kinase inhibitors;    PD-1 inhibitors;   

DOI  :  10.1186/s12957-023-02939-5

 received in 2022-09-15, accepted in 2023-02-11,  发布年份 2023

来源: Springer

【 摘 要 】

Background and objectiveThe recurrence occurs within 5 years in up to 70% of hepatocellular carcinoma (HCC) patients who received radical liver resection, and most patients are no longer suitable for repeat surgery. There are limited treatment options for unresectable recurrent HCC. This study aimed to explore the potential efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent HCC.MethodsForty-four patients with unresectable recurrent HCC after radical surgery between January 2017 and November 2022 were retrospectively collected and screened. All patients received the combination therapy of tyrosine kinase inhibitors (TKIs) and programmed cell death protein 1 (PD-1) inhibitors, and 18 of these patients received trans-arterial chemoembolization (TACE) or TACE combined with radiofrequency ablation (RFA). Two patients who received TKIs in combination with PD-1 inhibitors eventually obtained repeat surgery, with one patient undergoing a repeat hepatectomy and one patient receiving a liver transplant.ResultsThe median survival for these patients was 27.0 months (95% confidence interval [CI] 21.2, 32.8), with a 1-year overall survival (OS) rate of 83.6% (95% CI 77.9%, 89.3%). Median progression-free survival (PFS) was 15.0 months (95.0% CI 12.1, 17.9), with a 1-year PFS rate of 77.0% (95% CI 70.6%, 83.4%). The two patients who underwent repeat surgery had a survival time of 34 and 37 months after the combined treatment with no recurrence, respectively, as of November 2022.ConclusionThe combination of TKIs and PD-1 inhibitors for unresectable recurrent HCC is effective and can prolong the survival of patients in this group.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

Fig. 1

Fig. 1

Fig. 7

Fig. 4